Trials / Completed
CompletedNCT00087984
RNA-Loaded Dendritic Cell Cancer Vaccine
A Phase I/II Study To Examine The Safety, Feasibility, Immunological Response, And Measures Of Clinical Antitumor Activity After Administering Unselected, Autologous, Amplified Tumor Total RNA-Transfected, Dendritic Cell Vaccine (MB-002) To Patients With Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Argos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MB-002 | Dendritic Cell Immunotherapy |
Timeline
- Start date
- 2004-01-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2004-07-20
- Last updated
- 2013-02-18
Locations
5 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00087984. Inclusion in this directory is not an endorsement.